Kimberly Gold Blumenthal, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Drug Hypersensitivity | 89 | 2024 | 884 | 23.120 |
Why?
|
Penicillins | 45 | 2024 | 380 | 14.310 |
Why?
|
Anaphylaxis | 27 | 2024 | 746 | 7.120 |
Why?
|
beta-Lactams | 16 | 2023 | 159 | 6.810 |
Why?
|
Hypersensitivity | 26 | 2023 | 1102 | 6.160 |
Why?
|
Anti-Bacterial Agents | 55 | 2024 | 7172 | 5.970 |
Why?
|
Skin Tests | 29 | 2023 | 613 | 3.440 |
Why?
|
Vancomycin | 8 | 2022 | 501 | 2.460 |
Why?
|
Eosinophilia | 5 | 2023 | 541 | 2.420 |
Why?
|
Cephalosporins | 9 | 2023 | 203 | 2.420 |
Why?
|
Urticaria | 4 | 2022 | 150 | 2.350 |
Why?
|
Allergy and Immunology | 6 | 2020 | 169 | 2.070 |
Why?
|
Hypersensitivity, Immediate | 5 | 2023 | 337 | 1.830 |
Why?
|
Electronic Health Records | 25 | 2022 | 4467 | 1.750 |
Why?
|
Vaccines | 6 | 2022 | 823 | 1.650 |
Why?
|
Cefazolin | 5 | 2024 | 96 | 1.520 |
Why?
|
Allergens | 17 | 2022 | 1320 | 1.510 |
Why?
|
Desensitization, Immunologic | 8 | 2021 | 483 | 1.450 |
Why?
|
Exanthema | 5 | 2023 | 501 | 1.350 |
Why?
|
Soft Tissue Infections | 2 | 2021 | 155 | 1.300 |
Why?
|
Physicians, Women | 3 | 2023 | 486 | 1.150 |
Why?
|
Drug Eruptions | 4 | 2021 | 297 | 1.060 |
Why?
|
Documentation | 12 | 2022 | 871 | 1.020 |
Why?
|
Vaccination | 11 | 2022 | 3275 | 1.020 |
Why?
|
Humans | 164 | 2024 | 743811 | 0.950 |
Why?
|
Angioedema | 3 | 2022 | 187 | 0.920 |
Why?
|
Staphylococcal Infections | 3 | 2018 | 1400 | 0.900 |
Why?
|
Immunologic Tests | 3 | 2019 | 103 | 0.870 |
Why?
|
Vaccines, Synthetic | 4 | 2022 | 634 | 0.860 |
Why?
|
Inpatients | 10 | 2023 | 2515 | 0.840 |
Why?
|
Surgical Wound Infection | 4 | 2021 | 1539 | 0.780 |
Why?
|
Skin Diseases, Bacterial | 1 | 2021 | 66 | 0.780 |
Why?
|
Antibiotic Prophylaxis | 5 | 2024 | 638 | 0.780 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 2 | 2018 | 687 | 0.720 |
Why?
|
Immunization, Secondary | 1 | 2022 | 340 | 0.720 |
Why?
|
Physicians | 3 | 2022 | 4569 | 0.720 |
Why?
|
Erythema | 1 | 2021 | 257 | 0.700 |
Why?
|
Electronics, Medical | 1 | 2019 | 71 | 0.680 |
Why?
|
Food Hypersensitivity | 3 | 2022 | 622 | 0.670 |
Why?
|
Bacteremia | 2 | 2016 | 963 | 0.660 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 4 | 2018 | 2281 | 0.660 |
Why?
|
Viral Vaccines | 2 | 2022 | 636 | 0.650 |
Why?
|
Methicillin | 2 | 2016 | 59 | 0.610 |
Why?
|
RNA, Messenger | 11 | 2022 | 13028 | 0.610 |
Why?
|
Practice Guidelines as Topic | 7 | 2019 | 7270 | 0.560 |
Why?
|
Terminology as Topic | 2 | 2021 | 1546 | 0.540 |
Why?
|
Decision Support Systems, Clinical | 4 | 2020 | 1164 | 0.530 |
Why?
|
Decision Making, Computer-Assisted | 1 | 2016 | 150 | 0.530 |
Why?
|
Costs and Cost Analysis | 2 | 2020 | 1680 | 0.520 |
Why?
|
Diagnostic Tests, Routine | 2 | 2019 | 782 | 0.510 |
Why?
|
Female | 66 | 2023 | 380020 | 0.510 |
Why?
|
Drug Prescriptions | 2 | 2015 | 1636 | 0.510 |
Why?
|
Stevens-Johnson Syndrome | 2 | 2016 | 281 | 0.500 |
Why?
|
Cross Reactions | 4 | 2019 | 841 | 0.490 |
Why?
|
Nafcillin | 1 | 2014 | 25 | 0.490 |
Why?
|
Faculty, Medical | 2 | 2020 | 1181 | 0.480 |
Why?
|
Skin Diseases | 2 | 2021 | 1066 | 0.470 |
Why?
|
Consensus | 3 | 2023 | 2954 | 0.460 |
Why?
|
Biological Products | 1 | 2022 | 859 | 0.450 |
Why?
|
Male | 56 | 2023 | 349776 | 0.450 |
Why?
|
Immunoglobulin E | 6 | 2020 | 1463 | 0.440 |
Why?
|
Middle Aged | 43 | 2022 | 213241 | 0.440 |
Why?
|
Asthma | 4 | 2021 | 6010 | 0.440 |
Why?
|
Women's Health | 1 | 2022 | 2033 | 0.430 |
Why?
|
Schools, Medical | 1 | 2019 | 879 | 0.430 |
Why?
|
Retrospective Studies | 22 | 2023 | 77410 | 0.420 |
Why?
|
Anesthesia | 2 | 2020 | 1562 | 0.400 |
Why?
|
Boston | 7 | 2021 | 9310 | 0.400 |
Why?
|
Clostridium Infections | 1 | 2018 | 548 | 0.400 |
Why?
|
Influenza Vaccines | 1 | 2019 | 738 | 0.390 |
Why?
|
Education | 1 | 2014 | 543 | 0.380 |
Why?
|
Preoperative Care | 1 | 2020 | 2251 | 0.380 |
Why?
|
Cross-Sectional Studies | 12 | 2024 | 25032 | 0.380 |
Why?
|
Drug Utilization | 1 | 2017 | 1183 | 0.370 |
Why?
|
Academic Medical Centers | 2 | 2020 | 2760 | 0.370 |
Why?
|
Skin Pigmentation | 2 | 2023 | 282 | 0.360 |
Why?
|
United States | 21 | 2023 | 69859 | 0.360 |
Why?
|
Pharmaceutical Preparations | 5 | 2020 | 1070 | 0.360 |
Why?
|
Population Surveillance | 2 | 2019 | 2614 | 0.340 |
Why?
|
Pneumonia | 1 | 2021 | 2133 | 0.340 |
Why?
|
Aged | 30 | 2023 | 163178 | 0.340 |
Why?
|
Adult | 34 | 2022 | 213889 | 0.340 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2020 | 2027 | 0.320 |
Why?
|
Staphylococcus aureus | 1 | 2016 | 1453 | 0.310 |
Why?
|
Cohort Studies | 12 | 2021 | 40545 | 0.300 |
Why?
|
Data Collection | 1 | 2017 | 3339 | 0.300 |
Why?
|
Amoxicillin | 2 | 2019 | 169 | 0.290 |
Why?
|
Health Expenditures | 1 | 2020 | 2348 | 0.290 |
Why?
|
Outpatients | 4 | 2019 | 1488 | 0.270 |
Why?
|
Referral and Consultation | 1 | 2019 | 3530 | 0.270 |
Why?
|
Comorbidity | 2 | 2018 | 10380 | 0.250 |
Why?
|
Delivery of Health Care | 7 | 2022 | 5319 | 0.240 |
Why?
|
Anxiety | 1 | 2018 | 4288 | 0.240 |
Why?
|
Risk | 5 | 2019 | 9677 | 0.240 |
Why?
|
Sex Factors | 5 | 2021 | 10394 | 0.230 |
Why?
|
Dietary Supplements | 1 | 2016 | 3292 | 0.220 |
Why?
|
Latex | 1 | 2022 | 52 | 0.220 |
Why?
|
Incidence | 6 | 2021 | 20948 | 0.220 |
Why?
|
Rosaniline Dyes | 1 | 2021 | 51 | 0.200 |
Why?
|
Telemedicine | 1 | 2019 | 2874 | 0.200 |
Why?
|
Prospective Studies | 9 | 2023 | 53250 | 0.200 |
Why?
|
Registries | 6 | 2022 | 8090 | 0.200 |
Why?
|
Dermatology | 2 | 2021 | 872 | 0.200 |
Why?
|
Adverse Drug Reaction Reporting Systems | 2 | 2022 | 469 | 0.200 |
Why?
|
Immunoglobulin G | 3 | 2022 | 4561 | 0.190 |
Why?
|
Chickenpox | 1 | 2021 | 131 | 0.190 |
Why?
|
Risk Factors | 10 | 2022 | 72252 | 0.190 |
Why?
|
Syndrome | 2 | 2021 | 3249 | 0.190 |
Why?
|
IgG Deficiency | 1 | 2020 | 28 | 0.180 |
Why?
|
Prevalence | 7 | 2018 | 15211 | 0.180 |
Why?
|
Aged, 80 and over | 9 | 2021 | 57744 | 0.180 |
Why?
|
Vocabulary, Controlled | 2 | 2018 | 170 | 0.180 |
Why?
|
Immunoglobulin Isotypes | 1 | 2020 | 158 | 0.180 |
Why?
|
Natural Language Processing | 4 | 2021 | 1041 | 0.180 |
Why?
|
Texas | 1 | 2020 | 390 | 0.170 |
Why?
|
Herpes Zoster | 1 | 2021 | 264 | 0.170 |
Why?
|
Cross Infection | 2 | 2018 | 1416 | 0.170 |
Why?
|
Personnel, Hospital | 1 | 2021 | 283 | 0.170 |
Why?
|
Depression | 1 | 2018 | 7760 | 0.170 |
Why?
|
Career Mobility | 1 | 2020 | 262 | 0.160 |
Why?
|
Excipients | 3 | 2023 | 96 | 0.160 |
Why?
|
Odds Ratio | 3 | 2020 | 9848 | 0.160 |
Why?
|
Herpes Simplex | 1 | 2021 | 470 | 0.160 |
Why?
|
Immunity, Humoral | 1 | 2022 | 598 | 0.160 |
Why?
|
Nausea | 1 | 2021 | 674 | 0.160 |
Why?
|
Community Health Planning | 1 | 2018 | 165 | 0.160 |
Why?
|
Self Report | 2 | 2021 | 3550 | 0.150 |
Why?
|
Clindamycin | 1 | 2018 | 139 | 0.150 |
Why?
|
Shock, Cardiogenic | 1 | 2022 | 688 | 0.150 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2021 | 710 | 0.140 |
Why?
|
Pregnancy | 5 | 2023 | 29140 | 0.140 |
Why?
|
Decision Support Techniques | 2 | 2017 | 1956 | 0.140 |
Why?
|
beta-Lactamases | 1 | 2018 | 304 | 0.140 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2020 | 841 | 0.140 |
Why?
|
Hospitals, General | 1 | 2021 | 749 | 0.140 |
Why?
|
Allopurinol | 1 | 2018 | 190 | 0.140 |
Why?
|
Gout Suppressants | 1 | 2018 | 165 | 0.140 |
Why?
|
International Classification of Diseases | 2 | 2019 | 866 | 0.140 |
Why?
|
Expert Testimony | 1 | 2018 | 355 | 0.140 |
Why?
|
Infusions, Intravenous | 1 | 2021 | 2274 | 0.140 |
Why?
|
Vascular Grafting | 1 | 2017 | 143 | 0.130 |
Why?
|
Drug Resistance, Microbial | 1 | 2018 | 860 | 0.130 |
Why?
|
Carboplatin | 1 | 2018 | 801 | 0.130 |
Why?
|
Skin Diseases, Vesiculobullous | 1 | 2016 | 85 | 0.130 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2020 | 717 | 0.130 |
Why?
|
Computer Simulation | 2 | 2020 | 6188 | 0.130 |
Why?
|
Ambulatory Care | 2 | 2017 | 2707 | 0.130 |
Why?
|
Polyethylene Glycols | 1 | 2021 | 1181 | 0.130 |
Why?
|
Massachusetts | 3 | 2018 | 8660 | 0.130 |
Why?
|
Nephritis, Interstitial | 1 | 2016 | 154 | 0.130 |
Why?
|
Hypotension | 1 | 2021 | 884 | 0.130 |
Why?
|
Risk Adjustment | 1 | 2018 | 594 | 0.130 |
Why?
|
Policy | 1 | 2018 | 508 | 0.120 |
Why?
|
Quality Improvement | 2 | 2020 | 3750 | 0.120 |
Why?
|
Paclitaxel | 1 | 2021 | 1705 | 0.120 |
Why?
|
Blood Circulation | 1 | 2015 | 251 | 0.120 |
Why?
|
Breast Neoplasms | 1 | 2021 | 20827 | 0.120 |
Why?
|
Congresses as Topic | 1 | 2018 | 763 | 0.120 |
Why?
|
Data Mining | 1 | 2019 | 537 | 0.120 |
Why?
|
Proportional Hazards Models | 2 | 2021 | 12354 | 0.120 |
Why?
|
Hospitalization | 4 | 2021 | 10259 | 0.110 |
Why?
|
Databases as Topic | 1 | 2015 | 474 | 0.110 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2021 | 941 | 0.110 |
Why?
|
Survivors | 1 | 2023 | 2291 | 0.110 |
Why?
|
Standard of Care | 1 | 2017 | 564 | 0.110 |
Why?
|
United States Food and Drug Administration | 1 | 2020 | 1582 | 0.110 |
Why?
|
Internal Medicine | 1 | 2020 | 1009 | 0.110 |
Why?
|
Cisplatin | 1 | 2018 | 1662 | 0.110 |
Why?
|
International Cooperation | 1 | 2018 | 1419 | 0.100 |
Why?
|
Medication Adherence | 1 | 2023 | 2063 | 0.100 |
Why?
|
Cesarean Section | 1 | 2020 | 1365 | 0.100 |
Why?
|
Infusions, Parenteral | 1 | 2012 | 419 | 0.100 |
Why?
|
Professional Practice | 1 | 2014 | 326 | 0.100 |
Why?
|
Herpesvirus 6, Human | 1 | 2012 | 95 | 0.100 |
Why?
|
Nephritis | 1 | 2012 | 159 | 0.100 |
Why?
|
Cardiovascular Agents | 1 | 2017 | 850 | 0.090 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2022 | 1596 | 0.090 |
Why?
|
Surgical Procedures, Operative | 1 | 2022 | 1877 | 0.090 |
Why?
|
Patient Education as Topic | 1 | 2021 | 2278 | 0.090 |
Why?
|
Microbial Sensitivity Tests | 1 | 2016 | 1870 | 0.090 |
Why?
|
Eosinophils | 1 | 2015 | 954 | 0.090 |
Why?
|
Lymphatic Diseases | 1 | 2012 | 323 | 0.090 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2017 | 1516 | 0.090 |
Why?
|
Medical Order Entry Systems | 1 | 2015 | 545 | 0.090 |
Why?
|
Hepatitis | 1 | 2012 | 227 | 0.090 |
Why?
|
Respiration, Artificial | 1 | 2021 | 2568 | 0.090 |
Why?
|
Logistic Models | 3 | 2020 | 13404 | 0.090 |
Why?
|
Tachycardia | 1 | 2012 | 619 | 0.090 |
Why?
|
Education, Medical | 1 | 2021 | 1722 | 0.080 |
Why?
|
Physician-Patient Relations | 1 | 2022 | 3229 | 0.080 |
Why?
|
Young Adult | 4 | 2019 | 56392 | 0.080 |
Why?
|
Sulfonamides | 1 | 2018 | 1938 | 0.080 |
Why?
|
Patient Selection | 1 | 2021 | 4210 | 0.080 |
Why?
|
Anticonvulsants | 1 | 2018 | 1910 | 0.080 |
Why?
|
Ischemia | 1 | 2017 | 1907 | 0.080 |
Why?
|
Gastrointestinal Diseases | 1 | 2017 | 1171 | 0.080 |
Why?
|
Mortality | 1 | 2019 | 2862 | 0.080 |
Why?
|
Perioperative Care | 1 | 2015 | 1002 | 0.080 |
Why?
|
Artificial Intelligence | 1 | 2021 | 2210 | 0.080 |
Why?
|
Systematized Nomenclature of Medicine | 2 | 2018 | 36 | 0.070 |
Why?
|
Public Health | 1 | 2020 | 2603 | 0.070 |
Why?
|
Curriculum | 1 | 2020 | 3603 | 0.070 |
Why?
|
Arthroplasty, Replacement, Hip | 1 | 2018 | 1462 | 0.070 |
Why?
|
Arthroplasty, Replacement, Knee | 1 | 2018 | 1458 | 0.070 |
Why?
|
Peripheral Arterial Disease | 1 | 2017 | 1188 | 0.070 |
Why?
|
Age Factors | 2 | 2021 | 18355 | 0.070 |
Why?
|
Perioperative Period | 2 | 2019 | 256 | 0.070 |
Why?
|
Child | 5 | 2023 | 77637 | 0.070 |
Why?
|
Antineoplastic Agents | 2 | 2019 | 13691 | 0.070 |
Why?
|
Risk Assessment | 4 | 2022 | 23327 | 0.070 |
Why?
|
Europe | 3 | 2021 | 3336 | 0.060 |
Why?
|
Length of Stay | 1 | 2018 | 6311 | 0.060 |
Why?
|
Health Care Costs | 1 | 2018 | 3207 | 0.060 |
Why?
|
Severity of Illness Index | 2 | 2020 | 15526 | 0.060 |
Why?
|
Phenotype | 1 | 2022 | 16361 | 0.060 |
Why?
|
Cardiac Surgical Procedures | 1 | 2020 | 3537 | 0.060 |
Why?
|
Patient Acceptance of Health Care | 1 | 2018 | 3020 | 0.060 |
Why?
|
Immunologic Factors | 1 | 2014 | 1580 | 0.060 |
Why?
|
Fever | 1 | 2012 | 1616 | 0.060 |
Why?
|
Longitudinal Studies | 1 | 2020 | 13980 | 0.060 |
Why?
|
Time Factors | 3 | 2021 | 40038 | 0.060 |
Why?
|
Aztreonam | 1 | 2023 | 12 | 0.060 |
Why?
|
Endovascular Procedures | 1 | 2017 | 1980 | 0.060 |
Why?
|
Case-Control Studies | 1 | 2021 | 21733 | 0.060 |
Why?
|
Disease Management | 1 | 2014 | 2459 | 0.060 |
Why?
|
Algorithms | 2 | 2020 | 13869 | 0.060 |
Why?
|
Polysorbates | 1 | 2022 | 41 | 0.060 |
Why?
|
Quality of Life | 1 | 2023 | 12788 | 0.050 |
Why?
|
Pandemics | 1 | 2021 | 8385 | 0.050 |
Why?
|
Herpesvirus 3, Human | 1 | 2021 | 204 | 0.050 |
Why?
|
Models, Statistical | 1 | 2015 | 5100 | 0.050 |
Why?
|
Serum Sickness | 1 | 2019 | 28 | 0.040 |
Why?
|
Basophil Degranulation Test | 1 | 2019 | 16 | 0.040 |
Why?
|
Hospitals | 1 | 2023 | 3953 | 0.040 |
Why?
|
Follow-Up Studies | 3 | 2018 | 39001 | 0.040 |
Why?
|
Feedback | 1 | 2023 | 795 | 0.040 |
Why?
|
Models, Biological | 1 | 2015 | 9582 | 0.040 |
Why?
|
Infant | 2 | 2019 | 35122 | 0.040 |
Why?
|
Hypersensitivity, Delayed | 1 | 2018 | 484 | 0.040 |
Why?
|
Radioallergosorbent Test | 1 | 2017 | 15 | 0.040 |
Why?
|
Simplexvirus | 1 | 2021 | 803 | 0.040 |
Why?
|
Shellfish | 1 | 2017 | 38 | 0.040 |
Why?
|
Postoperative Period | 1 | 2022 | 1841 | 0.040 |
Why?
|
Child, Preschool | 2 | 2019 | 40964 | 0.040 |
Why?
|
Tryptases | 1 | 2018 | 190 | 0.040 |
Why?
|
Motion Therapy, Continuous Passive | 1 | 1996 | 10 | 0.040 |
Why?
|
Diagnosis, Differential | 1 | 2012 | 12954 | 0.040 |
Why?
|
Air Pollution, Indoor | 2 | 2001 | 857 | 0.040 |
Why?
|
Dermatitis | 1 | 2018 | 199 | 0.030 |
Why?
|
North America | 1 | 2019 | 1249 | 0.030 |
Why?
|
Retreatment | 1 | 2017 | 609 | 0.030 |
Why?
|
Th2 Cells | 1 | 2001 | 1061 | 0.030 |
Why?
|
Decision Trees | 1 | 2017 | 506 | 0.030 |
Why?
|
Adolescent | 4 | 2019 | 85729 | 0.030 |
Why?
|
Finger Injuries | 1 | 1996 | 139 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2022 | 2307 | 0.030 |
Why?
|
Drug Therapy, Computer-Assisted | 1 | 2015 | 204 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2018 | 10940 | 0.030 |
Why?
|
Markov Chains | 1 | 2017 | 968 | 0.030 |
Why?
|
Treatment Outcome | 3 | 2017 | 63042 | 0.030 |
Why?
|
ROC Curve | 1 | 2020 | 3527 | 0.030 |
Why?
|
Tendon Injuries | 1 | 1996 | 313 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 3874 | 0.030 |
Why?
|
Glycoproteins | 1 | 2001 | 2266 | 0.030 |
Why?
|
Neoplasms | 1 | 2021 | 21675 | 0.030 |
Why?
|
Antibodies, Neutralizing | 1 | 2022 | 1978 | 0.030 |
Why?
|
Databases, Factual | 2 | 2018 | 7729 | 0.030 |
Why?
|
Leadership | 1 | 2020 | 1357 | 0.020 |
Why?
|
Drug Interactions | 1 | 2015 | 1460 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 2017 | 1683 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2020 | 19894 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2017 | 15067 | 0.020 |
Why?
|
Postoperative Care | 1 | 1996 | 1485 | 0.020 |
Why?
|
User-Computer Interface | 1 | 2015 | 1431 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 2021 | 5388 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2020 | 3587 | 0.020 |
Why?
|
Inhalation Exposure | 2 | 2001 | 443 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2020 | 12243 | 0.020 |
Why?
|
Stents | 1 | 2017 | 3280 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2018 | 7784 | 0.020 |
Why?
|
Critical Illness | 1 | 2017 | 2670 | 0.020 |
Why?
|
Emergency Service, Hospital | 1 | 2021 | 7658 | 0.010 |
Why?
|
Dose-Response Relationship, Immunologic | 1 | 2001 | 370 | 0.010 |
Why?
|
Models, Immunological | 1 | 2001 | 527 | 0.010 |
Why?
|
Australia | 1 | 2000 | 1167 | 0.010 |
Why?
|
Respiratory Sounds | 1 | 2001 | 696 | 0.010 |
Why?
|
Thumb | 1 | 1996 | 227 | 0.010 |
Why?
|
Maternal Exposure | 1 | 2000 | 961 | 0.010 |
Why?
|
Life Style | 1 | 2001 | 3833 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 1996 | 8637 | 0.000 |
Why?
|
Infant, Newborn | 1 | 2000 | 25609 | 0.000 |
Why?
|